...
首页> 外文期刊>Scientific reports. >A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains
【24h】

A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains

机译:渗透性增加的药物用细菌外排泵抑制剂促进和恢复对多药物抗生素的抗生素的易感性铜绿假单胞菌菌株

获取原文
           

摘要

Resistance to antibiotics poses a major global threat according to the World Health Organization. Restoring the activity of existing drugs is an attractive alternative to address this challenge. One of the most efficient mechanisms of bacterial resistance involves the expression of efflux pump systems capable of expelling antibiotics from the cell. Although there are efflux pump inhibitors (EPIs) available, these molecules are toxic for humans. We hypothesized that permeability-increasing antimicrobial peptides (AMPs) could lower the amount of EPI necessary to sensitize bacteria to antibiotics that are efflux substrates. To test this hypothesis, we measured the ability of polymyxin B nonapeptide (PMBN), to synergize with antibiotics in the presence of EPIs. Assays were performed using planktonic and biofilm-forming cells of Pseudomonas aeruginosa strains overexpressing the MexAB-OprM efflux system. Synergy between PMBN and EPIs boosted azithromycin activity by a factor of 2,133 and sensitized P. aeruginosa to all tested antibiotics. This reduced several orders of magnitude the amount of inhibitor needed for antibiotic sensitization. The selected antibiotic-EPI-PMBN combination caused a 10 million-fold reduction in the viability of biofilm forming cells. We proved that AMPs can synergize with EPIs and that this phenomenon can be exploited to sensitize bacteria to antibiotics.
机译:抗生素抗性据世界卫生组织造成了主要的全球威胁。恢复现有药物的活动是解决这一挑战的有吸引力的替代方案。细菌抗性最有效的机制之一涉及能够从细胞中排出抗生素的流出泵系统的表达。虽然有流量泵抑制剂(EPIS)可用,但这些分子对人类有毒。我们假设渗透性增加的抗微生物肽(AMPs)可以降低敏化细菌的EPI的量,以抗生素是流出衬底的抗生素。为了测试这一假设,我们测量了多羟肽B非肽(PMBN)的能力,在EPIS存在下用抗生素协同效溶。使用Pseudomonas铜绿假单胞菌菌株的浮游和生物膜形成细胞进行测定,其过表达Mexab-OPRM Efflux系统。 PMBN和EPIS之间的协同作用将氮杂霉素活性提高了2,133倍,敏化的P.铜绿假单胞菌对所有测试的抗生素。这减少了几个数量级的抗生素敏化所需的抑制剂量。所选抗生素-PPI-PMBN组合在生物膜形成细胞的可行性降低了10百万倍。我们证明,AMPS可以与EPIS协同增长,并且可以利用这种现象来敏感细菌对抗生素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号